YUKA Is Building a National Telehealth Empire With A Proven Billion-Dollar Playbook
- Checkers
- 2 hours ago
- 4 min read
Med Holdings Group (OTCID: $YUKA) just put out its first press release in almost a year, and what's in it looks like the early stages of a playbook that has already produced billion-dollar outcomes in this sector. The company is building a hybrid model that combines a national telehealth platform with brick-and-mortar urology and men's health clinics across Florida, the fastest-growing large state in the country and one of the oldest demographically. Hims and Hers (NYSE: $HIMS) proved the telehealth side of this market could scale to a $3.7 billion valuation while Solaris Health proved the clinic rollup side could exit for $1.9 billion. Now, YUKA, with a market cap of $2.5 million and just 47.2 million shares outstanding, is attempting both at once.
The PR it just released is packed: advanced negotiations with Dr. Harvey Samowitz, a urologist with 30 years of experience and board certifications in urology and female pelvic medicine, two new Florida locations in Jupiter and Doral being negotiated, TotallBody.com
live nationally as a subscription telehealth service, and an accelerated timeline on both the audit and an upcoming FINRA ticker change.
Samowitz brings affiliations with some of the biggest names in the industry, including the American Urological Association, the American College of Surgeons, and a founding role at the American Society for Men's Health. Physicians with those credentials are increasingly valuable given what's happening in urology right now: HRSA projects an 18% shortfall by 2037, about a fifth of practicing urologists are over 65, and over 60% of U.S. counties don't have one at all, while demand keeps climbing as 11,500 Americans turn 65 every day and Medicare patients use urology services at three times the national rate. A doctor like Samowitz could go anywhere, so the fact that he's negotiating with YUKA suggests there's something here worth paying attention to.
The market YUKA operates in has size and a treatment gap that still hasn't closed. The urology market is valued at over $60 billion and is projected to hit just below $140 billion by 2032, ED treatment in the U.S. is a $1.36 billion market growing toward $2.16 billion, and testosterone replacement therapy is approaching $600 million. Roughly 30 million American men deal with ED but only about 25% are treating it, and that gap is what Hims and Hers built their entire business on when they launched in 2017 with the idea that men would pay for treatment if they could get it online without an awkward doctor visit. By 2024 the company had $1.48 billion in revenue and 2.2 million subscribers.
TotallBody.com is going after the same customer with a subscription model covering hormone therapy, GLP-1 weight loss, peptides, and regenerative medicine across 38 states, but YUKA isn't building a Hims clone. Hims started as a pure digital company and spent years scaling before realizing the limits of that approach, which is why they're now pushing into 20,000 retail locations and pharmacy partnerships to bolt on physical presence. The industry has been learning that hybrid works better than digital alone, and you can see it in what Amazon paid for One Medical: $3.9 billion for a company that combined telehealth with actual clinic locations. YUKA already has MedSmart Wellness Centers operating in Florida with two more in negotiation, so they're building the hybrid structure from the start rather than retrofitting it later.
The Florida expansion targets reinforce that management knows who they're selling to. Jupiter sits in Palm Beach County where median income hits $109,000, nearly a quarter of residents are over 65, and the millionaire population has grown 112% in the past decade. Doral skews younger with a median age of 37 but has grown over 275% since 2000 and serves as a Latin American business hub next to Miami International. Florida as a whole adds 300,000 people a year at double the national growth rate, over 20% of the population is Medicare-eligible, and there's no state income tax pushing wealthy retirees elsewhere. For a company building around urology and men's health, you couldn't design a better expansion corridor.
Solaris Health is the clearest proof of what this playbook can produce. The company launched as a urology rollup in 2020, grew to over 700 providers across 13 states, and
sold to Cardinal Health (NYSE: CAH) for $1.9 billion in November 2025. General Atlantic invested in U.S. Urology Partners earlier this year. Only about 7% of private-practice urologists are currently PE-backed, and Solaris's CEO described the consolidation cycle as being in the "third or fourth inning," which means most of the runway is still ahead. The economics are straightforward: acquire practices at 5-7x EBITDA, centralize operations, build regional density, and exit at 10-15x. YUKA is building that same structure in that same specialty in the state with the best patient demographics for it, and the Solaris exit just showed what the finish line looks like.
After a year of silence, YUKA just dropped a PR loaded with catalysts: the Samowitz negotiations, two new Florida locations, TotallBody live nationally, and an accelerated audit plus ticker change. Hims reached $3.7 billion building telehealth for men's health, Solaris reached $1.9 billion rolling up urology clinics, and YUKA is running both plays simultaneously in the state with the best demographics for it while its market cap sits at a paltry $2.5 million. The gap between where YUKA sits today and where these playbooks have gone is enormous, and everything in this PR suggests that closing it is exactly what management is setting up to do.
Disclaimer: Mt. Zion Market Ventures has received compensation for the creation and dissemination of this article. For more information, please visit opendisclose.com. The information provided here is not intended to be a comprehensive analysis of the subjects mentioned. All information, opinions, and forecasts contained herein should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities or related financial instruments. Investors should conduct their own research or consult with a qualified financial advisor before making any investment decisions. The author and publisher of this content are not responsible for any losses, damages, or other consequences that may result from the use of the information provided. Investing in stocks, including those mentioned here, involves risks, including the risk of loss.
